Bullish Moving Averages
3
Bearish Moving Averages
13
Back Stocks profile
Open Price
2109.00Prev. Close
2122.1000Volume
41100.00Value
86788815.00Market Cap Cr
84600.10
Price to Earnings
44.10
Price to Book Value
8.80
Dividend Yield
0.00
PE to Growth
0.90
Op Revenue TTM Cr
10334.77
Net Profit TTM Cr
1920.21
Cash From Operating Activity Cr
2152.44
Return on Equity %
20.43
EMA & SMA
Bullish Moving Averages
3
Bearish Moving Averages
13
DELIVERY AND VOLUME
17 May, 2024
Week
Month
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
PIVOT
First Resistance
2127.77
Second Resistance
2164.88
Third Resistance
2191.77
First Support
2063.77
Second Support
2036.88
Third Support
1999.77
Relative Strength Index
35.04
Money Flow Index
9.51
MACD
-42.19
MACD Signal
-16.93
Average True Range
93.12
Average Directional Index
18.84
Rate of Change (21)
-8.35
Rate of Change (125)
13.87
Commodity Channel Index
-147.3
Williams %R
-91.5
BETA
1 Month
-0.13
3 Month
0.68
1 Year
0.27
3 Year
PRICE CHANGE ANALYSIS
1 Week
Low
High
2060
2299
1 Month
Low
High
2060
2490
3 Months
Low
High
2016.55
2490
6 Months
Low
High
1821
2490
1 Year
Low
High
1242
2490
Mankind Pharma Ltd - 543904 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Postal Ballot NoticeMankind Pharma Q4 Results Review - Strong Performance From Formulation; Consumer Health Subdued: Dolat Capital
Export business shows exponential growth on low base and one-offsMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Conference Call for Q4FY24 - Audio RecordingMankind Pharma looking at acquisitions, keeping funds ready for an opportunity, says management
The company has an enabling or blanket approval to be ready for a big or small acquisitionMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of consolidated audited financial results for the quarter and financial year ended on March 31, 2024.Mankind Pharma Results Earnings Call for Q4FY24
Conference Call with Mankind Pharma Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.Q4FY24 Quarterly & FY24 Annual Result Announced for Mankind Pharma Ltd.
Pharmaceuticals company Mankind Pharma announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from Operations at Rs 2,441 crore, up by 19% YoY Domestic revenue at Rs 2,174 crore, up 10% YoY; Exports at Rs 267 crore, up 230% YoY EBITDA margin of 24.3%, and PAT margin of 19.5% Diluted EPS of Rs 11.7, up by 65% YoY (FV Re.1) FY24 Financial Highlights: Revenue from Operations at Rs 10,335 crore, up by 18% Domestic revenue at Rs 9,522 crore, up by 13%; Exports at Rs 813 crore, up by 175% EBITDA margin of 24.7%, and PAT margin of 18.8% Diluted EPS of Rs 47.7, up by 49% (FV Re.1) Cash flow from operations of Rs 2,152 crore, up by 19% Net cash balance of Rs 3,260 crore as on 31st March 2024 Rajeev Juneja – Vice Chairman & Managing Director said, “This year, we have achieved a revenue milestone of Rs 10,000 crore. and added 3 more brand families worth over Rs 100 crore raising the total to 23. Our strong revenue growth of 18% with EBITDA and PAT margin of ~25% and ~19% respectively is supported by an increase in Chronic share to 36% and growth in Modern Trade of over 50%. We have further strengthened our chronic product portfolio with strategic in-house launches coupled with in-licensing of products like Symbicort – a globally renowned inhaler from Astra Zeneca. Multiple technology led business transformation projects implemented across functions to further enhance efficiency and productivity laying the foundation for our next phase of growth.” Result PDFMankind Pharma Ltd - 543904 - Clarification On News Item Appearing In Www.Business-Standard.Com
Clarification on news item appearing in www.business-standard.comMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and financial year ended 31st March 2024.Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Financial Results for the quarter and financial year ended on March 31, 2024.The latest market price of Mankind Pharma Ltd. on NSE was Rs. 2111.65 as of today.
The opening share price of Mankind Pharma Ltd. was Rs. 2109.00 as of today.
The 52-week high share price of Mankind Pharma Ltd. was Rs. 2490.00.
The 52 week low share price of Mankind Pharma Ltd. was Rs. 1242.00.
Mankind Pharma Ltd. has a market cap of Rs. 84600.10 crore as of today. Please refer to the Fundamentals section for further details.
The PE ratio of Mankind Pharma Ltd. is 0.90. Please refer to the Fundamentals section for further details.
The operating revenue for Mankind Pharma Ltd. in the last FY was Rs. 10334.77 crore. Please refer to the Financials section for further details.
The Net Profit for Mankind Pharma Ltd. in the last FY was Rs. 1920.21 crore. Please refer to the Financials section for further details.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.
Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.
Please refer to the News section for the latest news about Mankind Pharma Ltd..